Glenmark Steps Closer To First NCE With Positive Phase II Data For Crofelemer; Gears Up For Larger Trials

MUMBAI - Years of racing to put an original compound into the market looks set to be one step closer for India's Glenmark Pharmaceuticals as the company announced successful completion of Phase II multi-center clinical trials in India for its first-in-class anti-diarrheal agent crofelemer